Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase of antitumour activity of bioreductive agents

British Journal of Cancer

Volumn 74, Issue SUPPL. XXVII, 1996, Pages

  Begleiter, A ^a,b   Leith, M K ^a,b   Curphey, T J ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c DARTMOUTH COLLEGE   (United States)

Author keywords

1,2 dithiole 3 thione; Bioreductive antitumour agent; DT diaphorase; EO9; Mitomycin C

Indexed keywords

1,2 DITHIOLE 3 THIONE DERIVATIVE; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ANTINEOPLASTIC AGENT; DICOUMAROL; MITOMYCIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); 1,2 DITHIOL 3 THIONE; 1,2-DITHIOL-3-THIONE; AZIRIDINE DERIVATIVE; INDOLE DERIVATIVE; MITOMYCIN; THIOKETONE; THIOPHENE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; LEUKEMIA L 5178 Y; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ARTICLE; BIOSYNTHESIS; BIOTRANSFORMATION; CELL CULTURE; DBA MOUSE; DRUG EFFECT; ENZYMOLOGY; LYMPHOMA; OXIDATION REDUCTION REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; BIOTRANSFORMATION; ENZYME INDUCTION; INDOLEQUINONES; INDOLES; LYMPHOMA; MICE; MICE, INBRED DBA; MITOMYCIN; NAD(P)H DEHYDROGENASE (QUINONE); OXIDATION-REDUCTION; THIONES; THIOPHENES; TUMOR CELLS, CULTURED;

EID: 0029950920     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. ADAMS GE AND STRATFORD IJ. (1994). Bioreductive drugs for cancer therapy: The search for tumor specificity. Int. J. Radiat. Oncol. Biol. Physics, 29, 231-238.
2. ATALLAH AS, LANDOLPH JR, ERNSTER L AND HOCHSTEIN P (1988). DT-diaphorase activity and the cytotoxicity of quinones in C3H/10T1/2 mouse embryo cells. Biochem. Pharmacol., 37, 2451-2459.
3. BEGLEITER A AND LEITH MK. (1990). Activity of quinone alkylating agents in quinone-resistant cells. Cancer Res., 50, 2872-2876
4. BEGLEITER A AND LEITH MK. (1995). Induction of DT-diaphorase by doxorubicin and combination therapy with mitomycin C in vitro. Biochem. Pharmacol., 50, 1281-1286.
5. BEGLEITER A, LEITH MK, MCCLARTY G, BEENKEN S, GOLDENBERG GJ AND WRIGHT JA. (1988). Characterization of L5178Y murine lymphoblasts resistant to quinone antitumor agents. Cancer Res., 48, 1727-1735.
6. BEGLEITER A, ROBOTHAM E, LACEY G AND LEITH MK. (1989). Increased sensitivity of quinone resistant cells to mitomycin C. Cancer Lett., 5, 173-176.
7. BELINSKY M AND JAISWAL AK. (1993). NAD(P)H:quinone oxidoreductasel (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev., 12, 103-117.
8. BENSON AM, HUNKELER MJ AND TALALAY P. (1980). Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc. Natl Acad. Sci. USA, 77, 5216-5220.
9. BEYER RE, SEGURA AGUILAR JE AND ERNSTER L. (1988). The anticancer enzyme DT diaphorase is induced selectively in liver during ascites hepatoma growth. Anticancer Res., 8, 233-238.
10. BUEDING E, DOLAN P AND LEROY JP. (1982). The antischistosomal activity of oltipraz. Res. Commun. Chem. Pathol. Pharmacol., 37, 293-303.
11. COIA LR. (1993). The use of mitomycin in esophageal cancer. Oncology (Basel), 50 Suppl 1, 53-62.
12. EGNER PA, KENSLER TW, PRESTERA T, TALALAY P, LIBBY AH, JOYNER HH AND CURPHEY TJ. (1994). Regulation of phase 2 enzyme induction by oltipraz and other dithiolethiones. Carcinogenesis, 15, 177-181.
13. FOLMAN RS. (1993). Experience with mitomycin in the treatment of non-small cell lung cancer. Oncology (Basel), 50 Suppl 1, 24-30.
14. GUSTAFSON DL AND PRITSOS CA. (1992). Bioactivation of mitomycin C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors. J. Natl Cancer Inst., 84, 1180-1185.
15. HENDRIKS HR, PIZAO PE, BERGER DP, KOOISTRA KL, BIBBY MC, BOVEN E, DREEF VAN DER MEULEN HC, HENRAR RE, FIEBIG HH, DOUBLE JA ET AL. (1993). EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur. J. Cancer, 29A, 897-906.
16. HODNICK WF AND SARTORELLI AC. (1993). Reductive activation of mitomycin C by NADH:cytochrome b5 reductase. Cancer Res., 53, 4907-4912.
17. HORTOBAGYI GN. (1993). Mitomycin: Its evolving role in the treatment of breast cancer. Oncology (Basel), 50 Suppl 1, 1-8.
18. JAISWAL AK. (1991). Human NAD(P)H:quinone oxidoreductase (NQO-1) gene structure and induction by dioxin. Biochemistry, 30, 10647-10653.
19. JAISWAL AK, BURNETT P, ADESNIK M AND MCBRIDE OW. (1990). Nucleotide and deduced amino acid sequence of a human cDNA (NQ02) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. Biochemistry, 29, 1899-1906.
20. JOSEPH P, JAISWAL AK, STOBBE CC AND CHAPMAN JD. (1994). The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles. Int. J. Radiat. Oncol. Biol. Physics, 29, 351-355.
21. KELLOFF GJ, MALONE WF, BOONE CW, SIGMAN CC AND FAY JR. (1990). Progress in applied chemoprevention research. Semin. Oncol., 17, 438-455.
22. KENSLER T, STYCZYNSKI P, GROOPMAN J, HELZLSOUER K, CURPHEY T, MAXUITENKO Y AND ROEBUCK BD. (1992). Mechanisms of chemoprotection by oltipraz. J. Cell Biochem. Suppl., 161, 167-172.
23. KEYES SR, FRACASSO PM, HEIMBROOK DC, ROCKWELL S, SLIGAR SG AND SARTORELLI AC. (1984). Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C. Cancer Res., 44, 5638-5643.
24. LI Y, LAFUENTE A AND TRUSH MA. (1994). Characterization of quinone reductase, glutathione and glutathione S-transferase in human myeloid cell lines: Induction by 1,2-dithiole-3-thione and effects on hydroquinone-induced cytotoxicity. Life Sciences, 54, 901-916.
25. MARSHALL RS, PATERSON MC AND RAUTH AM. (1991). DT-diaphorase activity and mitomycin C sensitivity in non-transformed cell strains derived from members of a cancer-prone family. Carcinogenesis, 12, 1175-1180.
26. PAN SS, ANDREWS PA, GLOVER CJ AND BACHUR NR. (1984). Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J. Biol. Chem., 259, 959-966.
27. PATTERSON AV, ROBERTSON N, HOULBROOK S, STEPHENS MA, ADAMS GE, HARRIS AL, STRATFORD IJ AND CARMICHAEL J. (1994). The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233). Int. J. Radiat. Oncol. Biol. Physics. 29, 369-372.
28. PLUMB JA, GERRITSEN M, MILROY R, THOMSON P AND WORKMAN P. (1994). Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int. J. Radiat. Oncol. Biol. Physics, 29, 295-299.
29. PRESTERA T, ZHANG Y, SPENCER SR, WILCZAK CA AND TALALAY P. (1993). The electrophile counterattack response: protection against neoplasia and toxicity. Adv. Enzyme Regul., 33, 281-296.
30. PROCHASKA HJ AND SANTAMARIA AB. (1988). Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers. Anal. Biochem., 169, 328-336.
31. RILEY RJ AND WORKMAN P. (1992). DT-diaphorase and cancer chemotherapy. Biochem. Pharmacol., 43, 1657-1669.
32. ROCKWELL S, KEYES SR AND SARTORELLI AC. (1989). Modulation of the cytotoxicity of porfiromycin by dicoumarol in vitro and in vivo. Anticancer Res., 9, 817-820.
33. ROCKWELL S, SARTORELLI AC, TOMASZ M AND KENNEDY KA. (1993). Cellular pharmacology of quinone bioreductive alkylating agents. Cancer Metastasis Rev., 12, 165-176.
34. ROSS D, SIEGEL D, BEALL H, PRAKASH AS, MULCAHY RT AND GIBSON NW. (1993). DT-diaphorase in activation and detoxification of quinones. Cancer Metastasis Rev., 12, 83-101.
35. SCHLAGER JJ AND POWIS G. (1990). Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int. J. Cancer, 45, 403-409.
36. SCHNALL S AND MACDONALD JS. (1993). Mitomycin therapy in gastric cancer. Oncology (Basel), 50 Suppl 1, 70-77.
37. SIEGEL D, GIBSON NW, PREUSCH PC AND ROSS D. (1990). Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res., 50, 7293-7300.
38. TWERDOK LE, REMBISH SJ AND TRUSH MA. (1992). Induction of quinone reductase and glutathione in bone marrow cells by 1,2-dithiole-3-thione: effect on hydroquinone-induced cytotoxicity. Toxicol. Appl. Pharmacol., 112, 273-281.
39. TWERDOK LE, REMBISH SJ AND TRUSH MA. (1993). Studies with 1,2-dithiole-3-thione as a chemoprotector of hydroquinone-induced toxicity to DBA/2-derived bone marrow stromal cells. Environmental Health Perspectives, 101, 172-177.
40. WALTERS RS, FRYE D, BUDZAR AU, HOLMES FA AND HORTOBAGYI N. (1992). A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer, 69, 476-481.
41. WALTON MI AND WORKMAN P. (1990). Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochem. Pharmacol., 39, 1735-1742.
42. WORKMAN P AND STRATFORD IJ. (1993). The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev., 12, 73-82.
43. YAO KS, XANTHOUDAKIS S, CURRAN T AND O'DWYER PJ. (1994). Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia. Mol. Cell Biol., 14, 5997-6003.